Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BTX-A51
i
Other names:
BTX-A51
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Edgewood Oncology
Drug class:
CDK7/9 inhibitor, Casein kinase 1 alpha inhibitor
‹
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
BTX-A51
Sensitive: C3 – Early Trials
BTX-A51
Sensitive
:
C3
BTX-A51
Sensitive: C3 – Early Trials
BTX-A51
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.